Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Congenital Bleeding Disorder: later-stage trial registry
A small indexed set (9 trials) with no open enrollment listed right now.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · none currently recruiting · #1,916 of 28,707 conditions by registered trial count
Congenital Bleeding Disorder: 9 US clinical trials tracked, none currently recruiting.
Congenital Bleeding Disorder is the subject of 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 6 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 9 of these trials.
Enrollment posture brief
Registry condition congenital-bleeding-disorder
OPEN 0 | RECR 0% | LATE 6 | EARLY 2 | RANK #1916 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Congenital Bleeding Disorder has no open enrollment in this registry pull (9 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Congenital Bleeding Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Congenital Bleeding Disorder is recruiting below its size-band peers.
0 of 9 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Congenital Bleeding Disorder research.
Novo Nordisk A/S accounts for 9 of 9 trials (100%). 1 distinct sponsors appear on at least one study for this condition label.
-
Most Congenital Bleeding Disorder trials plan to enrol fewer than 100 people.
Median target enrolment is 65 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.
-
Congenital Bleeding Disorder research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
9 total, page 1 of 1
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
Novo Nordisk A/S
NCT02568202
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Novo Nordisk A/S
NCT00984126
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
Novo Nordisk A/S
NCT01480180
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Novo Nordisk A/S
NCT01392547
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Novo Nordisk A/S
NCT01138501
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Novo Nordisk A/S
NCT02141074
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
Novo Nordisk A/S
NCT01467427
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Novo Nordisk A/S
NCT02490787
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Novo Nordisk A/S
NCT00108758
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Congenital Bleeding Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Congenital Bleeding Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Congenital Bleeding Disorder page
9 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Congenital Bleeding Disorder trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Novo Nordisk A/S sponsors the most Congenital Bleeding Disorder trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Congenital Bleeding Disorder condition card totals 9 registered trials; most-linked intervention nonacog beta pegol; top US site state Iowa. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.